The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Daniel R. Gomez, Andreas Rimner, Charles B. Simone, B. C.John Cho, Marc de Perrot, Alex Adjei, Raphael Bueno, Ritu R. Gill, David H. Harpole, Mary Hesdorffer, Fred R. Hirsch, Andrew A. Jackson, Harvey I. Pass, David C. Rice, Valerie W. Rusch, Anne S. Tsao, Ellen Yorke, Kenneth Rosenzweig

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. Methods: In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. Results: Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. Conclusion: The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.

Original languageEnglish (US)
Pages (from-to)1172-1183
Number of pages12
JournalJournal of Thoracic Oncology
Volume14
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

National Cancer Institute (U.S.)
Mesothelioma
Expert Testimony
Radiotherapy
Thorax
Pneumonectomy
Guidelines
Research
Neoplasms
Proton Therapy
Dose Fractionation
Therapeutics
Palliative Care
Clinical Trials
Radiation
Lung
Malignant Mesothelioma

Keywords

  • Consensus guidelines
  • Mesothelioma
  • Radiation therapy
  • Treatment recommendations

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma : Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. / Gomez, Daniel R.; Rimner, Andreas; Simone, Charles B.; Cho, B. C.John; de Perrot, Marc; Adjei, Alex; Bueno, Raphael; Gill, Ritu R.; Harpole, David H.; Hesdorffer, Mary; Hirsch, Fred R.; Jackson, Andrew A.; Pass, Harvey I.; Rice, David C.; Rusch, Valerie W.; Tsao, Anne S.; Yorke, Ellen; Rosenzweig, Kenneth.

In: Journal of Thoracic Oncology, Vol. 14, No. 7, 01.07.2019, p. 1172-1183.

Research output: Contribution to journalReview article

Gomez, DR, Rimner, A, Simone, CB, Cho, BCJ, de Perrot, M, Adjei, A, Bueno, R, Gill, RR, Harpole, DH, Hesdorffer, M, Hirsch, FR, Jackson, AA, Pass, HI, Rice, DC, Rusch, VW, Tsao, AS, Yorke, E & Rosenzweig, K 2019, 'The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation', Journal of Thoracic Oncology, vol. 14, no. 7, pp. 1172-1183. https://doi.org/10.1016/j.jtho.2019.03.030
Gomez, Daniel R. ; Rimner, Andreas ; Simone, Charles B. ; Cho, B. C.John ; de Perrot, Marc ; Adjei, Alex ; Bueno, Raphael ; Gill, Ritu R. ; Harpole, David H. ; Hesdorffer, Mary ; Hirsch, Fred R. ; Jackson, Andrew A. ; Pass, Harvey I. ; Rice, David C. ; Rusch, Valerie W. ; Tsao, Anne S. ; Yorke, Ellen ; Rosenzweig, Kenneth. / The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma : Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. In: Journal of Thoracic Oncology. 2019 ; Vol. 14, No. 7. pp. 1172-1183.
@article{77d796340fb8449ea45fb299a8540efc,
title = "The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation",
abstract = "Introduction: Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. Methods: In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. Results: Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. Conclusion: The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.",
keywords = "Consensus guidelines, Mesothelioma, Radiation therapy, Treatment recommendations",
author = "Gomez, {Daniel R.} and Andreas Rimner and Simone, {Charles B.} and Cho, {B. C.John} and {de Perrot}, Marc and Alex Adjei and Raphael Bueno and Gill, {Ritu R.} and Harpole, {David H.} and Mary Hesdorffer and Hirsch, {Fred R.} and Jackson, {Andrew A.} and Pass, {Harvey I.} and Rice, {David C.} and Rusch, {Valerie W.} and Tsao, {Anne S.} and Ellen Yorke and Kenneth Rosenzweig",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.jtho.2019.03.030",
language = "English (US)",
volume = "14",
pages = "1172--1183",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",

}

TY - JOUR

T1 - The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma

T2 - Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

AU - Gomez, Daniel R.

AU - Rimner, Andreas

AU - Simone, Charles B.

AU - Cho, B. C.John

AU - de Perrot, Marc

AU - Adjei, Alex

AU - Bueno, Raphael

AU - Gill, Ritu R.

AU - Harpole, David H.

AU - Hesdorffer, Mary

AU - Hirsch, Fred R.

AU - Jackson, Andrew A.

AU - Pass, Harvey I.

AU - Rice, David C.

AU - Rusch, Valerie W.

AU - Tsao, Anne S.

AU - Yorke, Ellen

AU - Rosenzweig, Kenneth

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Introduction: Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. Methods: In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. Results: Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. Conclusion: The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.

AB - Introduction: Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. Methods: In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. Results: Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. Conclusion: The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.

KW - Consensus guidelines

KW - Mesothelioma

KW - Radiation therapy

KW - Treatment recommendations

UR - http://www.scopus.com/inward/record.url?scp=85067574879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067574879&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2019.03.030

DO - 10.1016/j.jtho.2019.03.030

M3 - Review article

C2 - 31125736

AN - SCOPUS:85067574879

VL - 14

SP - 1172

EP - 1183

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -